Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy

BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy. Many mCRPC patients never receive chemotherapy and thus cannot benefit from abiraterone acetate; we evaluated this agent i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ryan, Charles J., Smith, Matthew R., de Bono, Johann S., Molina, Arturo, Logothetis, Christopher J., de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, JM, Ng, Siobhan, Carles, Joan, Mulders, Peter F.A., Basch, Ethan, Small, Eric J., Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D., Suttmann, Henrik, Gerritsen, Winald R., Flaig, Thomas W., George, Daniel J., Yu, Evan Y., Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S., Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I., Rathkopf, Dana E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3683570/
https://ncbi.nlm.nih.gov/pubmed/23228172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1209096
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi